Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781016 | 0.98 | NOS1 (0.36) | HTR1AHTR7NOS1TDO2PTGDR2 | |
| SCHEMBL3791444 | 0.96 | NOS3 (0.34) | HTR1AHTR7NOS1NOTUMUSP30 | |
| SCHEMBL3786616 | 0.93 | NOTUM (0.37) | NOTUMUSP30PDK2PDK4 | |
| SCHEMBL3787321 | 0.81 | PTGDR2 (0.40) | HTR1AHTR7PTGDR2PTGS2MEN1 | |
| SCHEMBL11567722 | 0.80 | TDO2 (0.42) | HTR1AHTR7NOS1TDO2PTGDR2 | |
| SCHEMBL3789911 | 0.80 | ABCB1 (0.36) | HTR1AHTR7PTGDR2PTGS2NOTUM | |
| SCHEMBL17061132 | 0.79 | PTGDR2 (0.42) | HTR1ANOS1PTGDR2PTGS2MEN1 | |
| SCHEMBL2652565 | 0.79 | PTGDR2 (0.42) | HTR1ANOS1PTGDR2PTGS2MEN1 | |
| SCHEMBL3789806 | 0.79 | ABCB1 (0.39) | HTR1AHTR7PTGDR2PTGS2NOTUM | |
| SCHEMBL30002535 | 0.79 | ABCB1 (0.39) | HTR1AHTR7PTGDR2PTGS2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | HTR1A 3657/4885HTR7 1295/4885NOS1 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.